Hype and high hopes

Article Abstract:

Issues are presented concerning the performance of biotechnology companies which have floated on the stock market. The fall in value of the shares of EpiTan from 20 Australian cents to 6 Australian cents per share is discussed.

EpiTan

---

Bird flu bonanza

Article Abstract:

Australian biotech companies, such as Biota Holdings, posted rise in share price. The increase is attributed to obtaining of marketing licenses on avian flu drugs.

Product development, Marketing procedures, Alliances, partnerships, Licensing/Sales Agreements, Prevention, Cooperative agreement for product marketing, Viral antigens, Marketing agreements, Avian influenza

---

Bad to worse

Article Abstract:

The reasons behind the fall of Australia's biotech stocks by 10.3%, for econd quarter 2005, are examined.

Forecasts, trends, outlooks, Industry forecasts

Similar abstracts:

• Abstracts: High hopes. Minchin hoses down CEOs. RBA attracts interest in difficult period
• Abstracts: Singo and his Magic Millions. Got their Mojo working. Adland pitches a new line
• Abstracts: AAPT wired and wireless. Going to pieces. Telstra be damned - or privatised
• Abstracts: Marketing's best and brightest. Adland's new broom. Four online people-meters vie to survive
• Abstracts: The right stuff. Take time for the spiritual side

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.